Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
|01 Dec 2021||$0.13||$-0.01||-7.69%||614,046||$0.13||$0.14||$0.12|
|30 Nov 2021||$0.13||$0.01||8.00%||37,710||$0.12||$0.13||$0.12|
|29 Nov 2021||$0.13||$-0.01||-7.69%||258,175||$0.12||$0.13||$0.12|
|26 Nov 2021||$0.13||$0.01||8.33%||398,143||$0.12||$0.13||$0.12|
|25 Nov 2021||$0.12||$0.00||0.00%||181,032||$0.12||$0.12||$0.12|
|24 Nov 2021||$0.12||$0.01||9.09%||711,820||$0.12||$0.12||$0.11|
|23 Nov 2021||$0.11||$-0.01||-8.70%||1,964,642||$0.12||$0.12||$0.11|
|22 Nov 2021||$0.12||$0.00||0.00%||278,735||$0.12||$0.12||$0.11|
|19 Nov 2021||$0.12||$0.01||9.09%||179,444||$0.12||$0.12||$0.12|
|18 Nov 2021||$0.11||$0.00||0.00%||727,925||$0.12||$0.12||$0.11|
|17 Nov 2021||$0.11||$-0.01||-8.33%||1,084,141||$0.12||$0.12||$0.11|
|16 Nov 2021||$0.12||$0.00||0.00%||185,789||$0.12||$0.12||$0.12|
|15 Nov 2021||$0.12||$0.00||0.00%||413,067||$0.13||$0.13||$0.11|
|12 Nov 2021||$0.12||$-0.01||-8.00%||365,786||$0.13||$0.13||$0.12|
|11 Nov 2021||$0.13||$0.01||8.33%||356,956||$0.12||$0.13||$0.12|
|10 Nov 2021||$0.12||$-0.01||-7.69%||273,377||$0.13||$0.13||$0.12|
|09 Nov 2021||$0.13||$0.00||0.00%||161,191||$0.13||$0.13||$0.13|
|08 Nov 2021||$0.13||$0.02||17.39%||465,288||$0.12||$0.13||$0.12|
|05 Nov 2021||$0.12||$0.00||0.00%||1,217,576||$0.13||$0.13||$0.11|
|04 Nov 2021||$0.12||$0.00||0.00%||429,096||$0.13||$0.13||$0.12|
|03 Nov 2021||$0.12||$-0.01||-8.00%||335,895||$0.12||$0.13||$0.12|
|02 Nov 2021||$0.13||$0.01||8.33%||120,682||$0.13||$0.13||$0.12|
|08 Apr 2021||David Wilson||Issued||35||$5,218||
|Mr Alan David Fisher||Non-Executive Director||Sep 2016||
Mr Fisher has proven experience in restoring and enhancing shareholder value. He spent 24 years at Coopers & Lybrand as Lead Advisory Partner where he headed and grew the Melbourne Corporate Finance Division. Following this tenure, Alan developed his own corporate advisory business specialising in M&A, business restructurings, strategic advice and capital raisings.
|Mr Aaron Weaver||Non-Executive Director||Jul 2020||
Mr Weaver is a Managing Director at Apeiron Investments focused on the life sciences sector. He also serves as Senior General Counsel and supports fundraising and investor relations activities at ATAI Life Sciences AG, a clinical stage biopharmaceutical company focused on the development of therapeutics for the treatment of mood disorders, addiction and anxiety. From 2013 - 2017, he was an investment banker at Credit Suisse in London within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies. He was a capital markets solicitor at Allen & Overy LLP, London from 2007 - 2013.
|Dr Errol B De Souza||Executive ChairmanExecutive Director||Aug 2016||
Dr De Souza has over 35 years' experience as an executive in the biopharmaceutical industry. He is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders. He is currently President and CEO of Neuropore Therapies Inc. and is the former President and CEO of US biotech companies Biodel Inc. (NASDAQ:BIOD), Archemix Corporation and Synaptic Pharmaceutical Corporation (NASDAQ:SNAP). Dr De Souza formerly held senior management positions at Aventis Pharmaceuticals, Inc. (now Sanofi) and its predecessor Hoechst Marion Roussel Pharmaceuticals, Inc. Most recently, he was Senior Vice President and Site Head of US Drug Innovation and Approval (R&D), at Aventis, where he was responsible for the discovery and development of drug candidates through Phase IIa clinical trials for CNS and inflammatory disorders. Prior to Aventis, he was a co-founder and Chief Scientific Officer of Neurocrine Biosciences (NASDAQ:NBIX). Dr De Souza has served on multiple editorial boards, National Institutes of Health (NIH) Committees and is currently a Director of several public and private companies.
|Mr David Ian Wilson||Non-Executive Director||Jun 2016||
Mr Wilson is Chairman and founding partner of WG Partners and has over 30 years' experience in investment banking in the City of London. Previously Mr Wilson was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. Mr Wilson was previously Senior Independent Director of Optos plc.
|Dr Jane Ryan||Non-Executive Director||Sep 2020||
Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many fundraising campaigns and licensing initiatives including the awarding of a US Government contract. Jane is currently a Non-Executive Director of Anatara Lifesciences Ltd.
|Mr Mitchell D Kaye||Non-Executive Director||Nov 2018||
Mr Kaye joined BVF Partners LP in 2013. Mr Kaye was the founding member of Xmark Opportunity Partners, LLC. He ran the two funds from 2001-2008 and 1996-2001, respectively. Mr Kaye was the Founder of MedClaims Liaison, LLC. From 2008-2010, Mr Kaye was a Managing Director with Navigant Capital Advisors. He has served on the boards of several private and public companies, as well as the board of the New York Alzheimer's Association.
|Mr Peter Miles Winston Davies||Non-Executive Director||Jul 2021||
Mr Davies has a 15-year of experience in the financial services industry with multi-sector and multifunction knowledge. He has experience in advising private and public company Board of Directors and shareholders of businesses. He has completed numerous M&A transactions across a range of sectors including healthcare, along with experience in capital raising and restructuring opportunities during his time at Rothschild & Co. Mr Davies is currently an Investment Professional at Apeiron Investments Group and is Chief Business Officer for Leaf4Life Inc.
|Ms Suzanne Irwin||Company Secretary||Apr 2021||
|Adrian Hinton||Chief Financial Officer||
|Suzanne Irwin||Company Secretary||